Suneel Gupta is Chief Development Officer of Protagonist Therapeutics, Inc.
In the past he was Senior Vice President for Johnson & Johnson and VP-Clinical Pharmacology & Product Discovery at ALZA Corp. (a subsidiary of Johnson & Johnson) and Chief Scientific Officer of Impax Pharmaceuticals, Inc.
Dr. Gupta received a doctorate from The University of Manchester.
|04/26/2022||40,000||Derivative/Non-derivative trans. at $7.38 per share.||295,200|
|02/28/2022||649||Derivative/Non-derivative trans. at $24.28 per share.||15,758|
|02/15/2022||12,500||Award at $0 per share.||0|
|02/26/2021||12,000||Award at $0 per share.||0|
|12/03/2019||30,000||Acquisition at $5.13 per share.||153,900|
|02/28/2019||7,500||Award at $0 per share.||0|